Combined hormone therapy increases lobular breast cancer risk
Fred Hutchinson Cancer Research Center leads first study designed to evaluate the association between combined HRT use and the risk of lobular breast cancers. – Postmenopausal women who take combined estrogen/progestin hormone-replacement therapy for three years or more face a fourfold increased risk of developing various forms of lobular breast cancer, according to new findings by researchers.